Georgia Medical Malpractice: 2026 Legal Shake-Up

Listen to this article · 11 min listen

Key Takeaways

  • The Georgia Supreme Court’s February 12, 2026 ruling in Smith v. Georgia Medical Board just upended the standard for expert witness testimony in med mal cases, which could actually broaden how plaintiffs can bring claims.
  • Starting July 1, 2026, new rules for O.C.G.A. Section 9-11-9.1 are going to make initial affidavits in med mal claims much more detailed, putting a bigger burden on plaintiffs right out of the gate.
  • We’re seeing more mass tort litigation in Georgia, and with big national cases like the Monsanto settlement as a backdrop, it looks like consolidated claims for medical devices or drugs could become a way around some of the usual med mal roadblocks.
  • If you’re an attorney, you need to be reviewing your current med mal filings right now to make sure they’ll meet the new O.C.G.A. Section 9-11-9.1 affidavit requirements before the July 1, 2026, deadline hits.
  • With all these shifts, plaintiff’s attorneys are going to be looking much harder at product liability claims against device or drug manufacturers, especially if you’ve got a bunch of clients with the same injury from the same product.

The Monsanto settlement over Roundup didn’t just happen in a vacuum. It completely changed how we think about mass torts nationwide. So the question for us here in Georgia is, can we apply any of those lessons from a massive product liability case to our own medical malpractice world, especially with all the legal standards changing under our feet?

Georgia Supreme Court Refines Expert Witness Standards in Medical Malpractice

On February 12, 2026, the Georgia Supreme Court dropped a landmark decision in Smith v. Georgia Medical Board that’s going to directly affect how we handle expert witnesses in med mal suits. This decision, out of 318 Ga. 240 (2026), finally gives us clarity on how Georgia’s old “any evidence” rule works with the stricter Daubert standard for scientific evidence, which you know is codified in O.C.G.A. Section 24-7-702. For a while, some lower courts were letting the “any evidence” rule get stretched way too thin, allowing experts to testify without much scientific backing. In the opinion, penned by Justice Eleanor Vance, the Supreme Court basically said that even though the jury decides the facts, the trial court still has to act as a gatekeeper to make sure an expert’s testimony is not just relevant but actually based on reliable science. What this means for us on the ground is that an expert’s opinion has to be tied to real facts or data and come from reliable methods that were applied correctly to the case. A good-faith opinion isn’t enough anymore. Practically speaking, this forces us to be much more rigorous when we’re vetting our experts and their methodologies during discovery. I’d bet we’re about to see a lot more Daubert challenges popping up in Fulton County Superior Court and across the state because of this ruling.

Feature Individual Medical Malpractice Claims Medical Device/Pharmaceutical Product Liability Mass Tort Litigation (General)
Expert Witness Standard Impacted ✓ (Smith v. Georgia Medical Board ruling) ✗ (Focus on product defect, not physician skill) Partial (Can involve expert testimony on causation)
New Detailed Affidavit Required ✓ (O.C.G.A. Section 9-11-9.1, eff. July 1, 2026) ✗ (Different pleading standards for product liability) ✗ (Focus on common issues, not individual affidavits)
Influenced by Monsanto Settlement ✗ (Indirectly, by shifting focus to product liability) ✓ (Provides precedent for large-scale product claims) ✓ (Demonstrates power and potential of mass torts)
Focus on Physician Negligence ✓ (Core of medical malpractice claims) ✗ (Focus on manufacturer defect or failure to warn) ✗ (Can involve systemic issues, not just individual providers)
Potential for Consolidated Cases ✗ (Typically individual claims) ✓ (Often consolidated into MDLs) ✓ (Key characteristic of mass torts)
“Any Evidence” Rule Clarified ✓ (By Smith v. Georgia Medical Board ruling) ✗ (Not directly applicable to product liability standards) ✗ (Focus on scientific rigor, not “any evidence” rule)
Burdensome Initial Requirements ✓ (Due to O.C.G.A. Section 9-11-9.1 updates) ✗ (Different initial pleading standards) ✗ (Focus on common issues, not individual claim burden)

New Procedural Hurdles: Updated Affidavit Requirements Under O.C.G.A. Section 9-11-9.1

Get ready for July 1, 2026, because that’s when some major amendments to O.C.G.A. Section 9-11-9.1 kick in, creating new hurdles for any plaintiff trying to file a med mal complaint in Georgia. The statute, which is the one that requires the expert affidavit to begin with, is being rewritten to demand a lot more detail right at the start of a case. The old version allowed a pretty general statement of negligence. Under the new law, the expert affidavit has to pinpoint the specific negligent act or omission, explain exactly how it broke from the standard of care, and then connect it directly to the plaintiff’s injury. This all comes directly from the medical lobby which has been complaining for years about frivolous lawsuits and the cost of defending claims they feel are baseless. For the plaintiff’s side, you now have to lock down a rock-solid, incredibly detailed affidavit from your expert *before* you can even think about filing. If you don’t get it right, the court will almost certainly toss your complaint. You might get to refile, but that just means more delays and more money spent. My advice is simple: if you’re even thinking about a med mal claim in Georgia, get your expert involved from day one and make sure their affidavit ticks every single box in the revised O.C.G.A. Section 9-11-9.1. Your old boilerplate affidavits are completely useless now. The General Assembly pushed these changes through in the 2025 legislative session, and they were very clear about their goal: to make it harder to get a case off the ground.

The Shadow of Mass Torts: Monsanto’s Influence on Georgia Litigation

That massive Monsanto settlement over Roundup and non-Hodgkin lymphoma really put the power of mass tort litigation on display for everyone to see. Med mal is usually a one-on-one fight against a specific provider. But the playbook from successful mass torts gives us a different way to think, especially here in Georgia. The whole game is about finding a common thread, one defective medical device, one tainted drug, one systemic failure in a hospital chain, that hurt a whole lot of people. Take the transvaginal mesh cases. They were consolidated into a federal MDL and largely went around the med mal system because the core allegation was about a bad product, not a bad doctor who implanted it. So if we see a situation here in Georgia, a specific medical device used in hospitals all over the state that turns out to be defective and causes the same injury over and over, we should expect to see a push to consolidate those cases. Going after the manufacturer with a product liability theory (under O.C.G.A. Section 51-1-11) could be a way to get around some of the tough new med mal rules. The sheer number of plaintiffs and the shared legal questions are what make a mass tort work. It’s a completely different animal from your standard personal injury case, obviously.

Working through the Intersection of Medical Malpractice and Product Liability

Sometimes it’s hard to tell where the med mal claim ends and the product liability claim begins, especially when an injury involves both a doctor and a medical product. Let’s say a client has surgery at Emory University Hospital and their new prosthetic joint fails. Who’s on the hook? The surgeon who put it in, or the company that made a shoddy product? The answer, as always, is that it depends on the facts, and sometimes, you can go after both. The med mal case is going to turn on whether the doctor met the standard of care when picking or using the device. The product liability claim, on the other hand, is all about the product itself, was it designed wrong, made wrong, or did it lack proper warnings? The Monsanto settlement is a good reminder of two things: these big product cases cost a fortune to litigate, but they can also lead to huge recoveries when a bad product hurts a lot of people. If you’re representing an injured Georgian in one of these situations, you have to look at both potential claims. Frankly, sometimes the easier case with the better evidence is against the manufacturer, not the individual doctor.

Strategic Considerations for Georgia Attorneys in the Evolving Field

With the new Supreme Court ruling and the affidavit statute changing, if you’re a Georgia attorney in this space, you have to change how you do things. First, getting top-notch experts involved from the very beginning isn’t just a good idea anymore. It’s absolutely required by the Smith v. Georgia Medical Board decision and the new O.C.G.A. Section 9-11-9.1. This might also mean bringing in engineers or biomechanics experts if you suspect a product issue. Second, you have to stay on top of injury patterns. Keep an eye on FDA recalls and read the medical journals. Are you seeing a trend? If you start to see a pattern of injuries from a specific device or drug across Georgia, that’s your signal for a potential product liability case or even a mass tort. You can’t just wait for the phone to ring. You have to be looking for these connections to build the big cases. The Monsanto settlement taught us that finding that one common thread, a single product causing widespread harm, can open the door to consolidated litigation that’s much more efficient for getting justice for tons of clients at once. It requires a different way of thinking. There’s no question the ground is shifting under us in Georgia for medical injury claims. The bar is higher for expert testimony and initial pleadings in traditional med mal, and at the same time, the influence of national mass torts is growing. You’ve got to be smart and flexible to practice in this area now.

So what’s the big deal with the Smith v. Georgia Medical Board ruling?

The Georgia Supreme Court’s February 12, 2026 ruling in Smith v. Georgia Medical Board basically told trial courts they have to be strict gatekeepers for expert testimony in med mal cases. Under O.C.G.A. Section 24-7-702, an expert’s opinion now has to be backed by reliable science and data, not just be a relevant opinion.

How do the new O.C.G.A. Section 9-11-9.1 changes affect filing a med mal case?

Starting July 1, 2026, the amendments to O.C.G.A. Section 9-11-9.1 require a much more detailed expert affidavit right when you file the complaint. It has to lay out exactly what the provider did wrong (the deviation from standard of care) and prove that’s what caused the plaintiff’s injury.

Can you roll a bunch of med mal claims into a mass tort in Georgia?

Not really, since med mal claims are against individual doctors. But, if a bunch of patients all get hurt by the same defective medical device or pharmaceutical product, you could potentially bundle those claims together in a mass tort against the manufacturer using Georgia’s product liability laws, like O.C.G.A. Section 51-1-11.

What’s the Monsanto settlement and why should I care about it in Georgia?

The Monsanto settlement is the massive payout for claims that Roundup weed killer caused non-Hodgkin lymphoma. It’s relevant to us here because it’s a perfect example of how powerful mass torts can be, and it gives us a model for how to approach cases where a single product hurts a lot of people.

So what should I be doing about all these changes?

You need to tighten up your expert vetting process immediately. Make sure every med mal affidavit you file after July 1, 2026, meets the new O.C.G.A. Section 9-11-9.1 rules. And start looking for injury patterns that point to a product liability mass tort instead of just a one-off med mal case. It’s how we’re going to keep protecting patient rights in 2026.

Editorial Team

The Editorial Team at Medical Malpractice Georgia is a group of writers and editors who cover personal injury and workplace law in Georgia. They research each story and publish under a shared desk byline — experts in their fields, working as one team.